| Nation-Wide Retrospective Analysis of Allogeneic Stem Cell Transplantation in Patients with Multiple Myeloma: A Study from Korean Multiple Myeloma Working Party (KMM1913) |
Ho-Jin Shin1
, Do-Young Kim1, Kihyun Kim2, Chang-Ki Min3, Je-Jung Lee4, Yeung-Chul Mun5, Won-Sik Lee6, Sung-Nam Lim7, Jin Seok Kim8, Joon Ho Moo9, Da Jung Kim10, Soo-Mee Bang11, Jong-Ho Won12, Jae-Cheol Jo13, Young Il Koh14 |
1Division of Hematology/Oncology, Department of Internal Medicine, School of Medicine, Medical Research Institute, Pusan National University Hospital, Busan, Korea
2Department of Internal Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea
3Division of Hematology, Department of Internal Medicine, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea
4Department of Hematology/Oncology, Chonnam National University Hwasun Hospital, Hwasun, Korea
5Department of Internal Medicine, Ewha Womans University School of Medicine, Seoul, Korea
6Department of Internal Medicine, Inje University Busan Paik Hospital, Busan, Korea
7Department of Internal Medicine, Haeundae Paik Hospital, Inje University College of Medicine, Busan, Korea
8Division of Hematology, Department of Internal Medicine, Severance Hospital, Yonsei University College of Medicine, Seoul, Korea
9Department of Hematology/Oncology, Kyungpook National University Hospital, Daegu, Korea
10Division of Hematology-Oncology, Department of Internal Medicine, Kosin University College of Medicine, Busan, Korea
11Department of Internal Medicine, Seoul National University Bundang Hospital, Seongnam, Korea
12Division of Hematology & Oncology, Department of Internal Medicine, Soonchunhyang University Seoul Hospital, Seoul, Korea
13Department of Hematology and Oncology, Ulsan University Hospital, University of Ulsan College of Medicine, Ulsan, Korea
14Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Korea
|
|
|
|
Received: January 21, 2024; Accepted: February 29, 2024. Published online: March 4, 2024. |
|
|
|
| ABSTRACT |
Purpose
The role of allogeneic stem cell transplantation (alloSCT) in multiple myeloma (MM) treatment remains controversial. We conducted a retrospective, multicenter, nationwide study in Korea to evaluate the outcomes of alloSCT in Asian patients with MM.
Materials and Methods
Overall, 109 patients with MM who underwent alloSCT between 2003 and 2020 were included in this study. Data were collected from the Korean Multiple Myeloma Working Party Registry.
Results
The overall response rate and stringent complete response (sCR) plus CR rates were 67.0 and 46.8%, respectively, after alloSCT. At a median follow-up of 32.5 months, the 3-year probability of progression-free survival (PFS) and overall survival (OS) rates were 69.3 and 71.8%, respectively. The 3-year probabilities of OS rates in the upfront alloSCT, tandem auto-alloSCT, and later alloSCT groups were 75.0, 88.9, and 61.1%, respectively. Patients who achieved CR before or after alloSCT had significantly longer OS (89.8 vs. 18 months and 89.8 vs. 15.2 months, respectively). Even though patients who did not achieve CR prior to alloSCT, those who achieve CR after alloSCT had improved PFS and OS compared to those who had no achievement of CR both prior and after alloSCT. Patients who underwent alloSCT with 1–2 prior treatment lines had improved PFS (22.4 vs. 4.5 months) and OS (45.6 vs. 15.3 months) compared to those with three or more prior treatment lines.
Conclusion
AlloSCT may be a promising therapeutic option especially for younger, chemosensitive patients with earlier implementation from relapse.
|
| Key words:
Multiple myeloma, Hematopoietic stem cell transplantation, Disease status, Survival |
|
PDF Links
Full text via DOI
Download Citation 
